AbbVie Seeks New Indication for IMBRUVICA® in Pediatric Patients with Chronic Graft Versus Host Disease Pharmaceutical Investing
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer Pharmaceutical Investing
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates Pharmaceutical Investing
NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS Market News
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1... Pharmaceutical Investing
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy , from Bristol Myers Squibb Pharmaceutical Investing
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo plus Yervoy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma... Pharmaceutical Investing
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ?1% Pharmaceutical Investing
Potent Ventures Establishes New Partnership with New York Based "The Bee Conservancy" to Enact Its Purpose-Driven Keystone Species Strategy for the Gummy Project Biotech Investing
Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society Annual Meeting Pharmaceutical Investing
